Zenosoft Biopharma

Zenas BioPharma is a clinical-stage immunology-focused biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. Its lead franchise, obexelimab, is a bifunctional monoclonal antibody designed to co-engage CD19 and Fc gamma receptor IIb to inhibit B-cell activity without depleting B cells, with a Phase 3 program in immunoglobulin G4-related disease and additional development in multiple sclerosis and systemic lupus erythematosus. The company is also advancing orelabrutinib, an oral, CNS-penetrant Bruton's tyrosine kinase inhibitor for progressive multiple sclerosis. Beyond its lead assets, Zenas is building a broader immunology pipeline that includes early-stage oral and biologic programs such as ZB021, ZB022, ZB002 and ZB004. The company operates as a global biotech with roots in the U.S. and China and has used licensing and collaboration deals to expand and regionalize its portfolio.